Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
|Articles|August 11, 2021
Packaging Components for Parenteral Drug Development
Author(s)BioPharm International Editors
Datwyler offers the StarterPack packaging system designed to aid in the development of parenteral drug packaging.
Advertisement
Packaging component supplier Datwyler has announced the StarterPack packaging system designed to support parenteral drug development by providing components that offer sealing compatibility to prevent leaks or other seal integrity concerns throughout the manufacturing and handling process.
Developed in collaboration with specialty glass maker Schott, the StarterPack has Datwyler’s OmniFlex stoppers and Prime Caps, along with Schott’s adaptiQ vials.
The OmniFlex stopper is sprayed with a proprietary fluoropolymer designed to provide a barrier between drug and rubber to minimize extractables and leachables.
The Prime Caps, designed for high-speed filling lines, come in two sizes. A center-gated disc is designed to promote enhanced machinability, low bioburden and particulate levels, and container closure integrity.
The StarterPack was introduced to North American market on Aug. 11, 2021, at CPHI North America.
Source:
Advertisement
Related to this article
Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Phio's PH-762 posted a 70% response rate in skin cancer, supporting its FDA briefing package for a planned phase 2b trial.
Advertisement
Advertisement